Download PDF
Dtsch Med Wochenschr 2022; 147(23): 1537-1544
DOI: 10.1055/a-1810-9318
Dossier

Peripartale Kardiomyopathie

Peripartum Cardiomyopathy
Tobias Jonathan Pfeffer
,
Tobias König
,
Dominik Berliner
,
Johann Bauersachs
› Further Information
Also available at
    Permissions and Reprints

Die peripartale Kardiomyopathie (PPCM) ist eine Herzerkrankung, die zuvor herzgesunde Frauen kurz vor oder in den Monaten nach der Entbindung betrifft. In den letzten Jahren konnten Studien zu einem besseren Verständnis der Erkrankung beitragen. Dieser Beitrag bietet einen Überblick über den aktuellen Wissensstand zur Pathophysiologie und dem klinischen Bild der PPCM und fasst die aktuellen Empfehlungen zur Behandlung der PPCM zusammen.

Abstract

Peripartum cardiomyopathy (PPCM) is a rare but potentially life-threatening heart disease, with onset in the last month of pregnancy or in the first months after delivery in previously heart-healthy women. PPCM patients typically present with heart failure due to left ventricular (LV) dysfunction with an LV ejection fraction (EF) < 45 %. In the last years clinical and experimental studies contributed to a better understanding of the pathophysiology and the clinical course of PPCM. In the context of oxidative stress, the nursing hormone prolactin is cleaved into a smaller antiangiogenic and proapoptotic 16k Da form, leading to myocardial dysfunction. In an animal model this can be prevented by treatment with the dopamine agonist bromocriptine, which suppresses prolactin release. This therapeutic approach was confirmed in several clinical studies. Therefore, the current guidelines recommend a treatment consisting of a heart failure treatment according to current guidelines in combination with the dopamine agonist bromocriptine. If the diagnosis is made early and the treatment is started immediately, the prognosis is good compared to other forms of cardiomyopathies, as LV function recovers in most cases.

In the acute phase the severity of heart failure differs among PPCM patients. Some patients present with mild forms, whereas some PPCM patients display severely reduced LV function and cardiogenic shock. Especially the latter cases are still challenging, as treatment with β1-adrenergic receptor agonists is associated with progression of heart failure and a worse cardiac outcome. Therefore, patients with cardiogenic shock complicating PPCM should be treated in centers experienced in mechanical circulatory support in combination with bromocriptine treatment.

Schlüsselwörter

peripartale Kardiomyopathie - akute Herzinsuffizienz - chronische Herzinsuffizienz

Key words

peripartum Cardiomyopathy - acute heart failure - chronic heart failure


Publication History

Article published online:
16 November 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Bauersachs J, Konig T, van der Meer P. et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2019; 21 (07) 827-843
    CrossrefPubMedGoogle Scholar
  • 2 Sliwa K, Bauersachs J, Arany Z. et al. Peripartum cardiomyopathy: from genetics to management. Eur Heart J 2021; 42 (32) 3094-3102
    CrossrefPubMedGoogle Scholar
  • 3 Hilfiker-Kleiner D, Kaminski K, Podewski E. et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007; 128 (03) 589-600
    CrossrefPubMedGoogle Scholar
  • 4 Patten IS, Rana S, Shahul S. et al Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012; 485 7398 333-338
    CrossrefPubMedGoogle Scholar
  • 5 Halkein J, Tabruyn SP, Ricke-Hoch M. et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 2013; 123 (05) 2143-2154
    CrossrefPubMedGoogle Scholar
  • 6 Hoes MF, Bomer N, Ricke-Hoch M. et al. Human iPSC-Derived Cardiomyocytes of Peripartum Patients With Cardiomyopathy Reveal Aberrant Regulation of Lipid Metabolism. Circulation 2020; 142 (23) 2288-2291
    CrossrefPubMedGoogle Scholar
  • 7 Arrigo M, Blet A, Mebazaa A. Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD. Eur Heart J 2017; 38 (35) 2680-2682
    CrossrefPubMedGoogle Scholar
  • 8 Sliwa K, Hilfiker-Kleiner D, Petrie MC. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12 (08) 767-778
    CrossrefPubMedGoogle Scholar
  • 9 Ersbøll AS, Johansen M, Damm P. et al. Peripartum cardiomyopathy in Denmark: a retrospective, population-based study of incidence, management and outcome. Eur J Heart Fail 2017; 19 (12) 1712-1720
    CrossrefPubMedGoogle Scholar
  • 10 Irizarry OC, Levine LD, Lewey J. et al. Comparison of Clinical Characteristics and Outcomes of Peripartum Cardiomyopathy Between African American and Non-African American Women. JAMA Cardiol 2017; 2 (11) 1256-1260
    CrossrefPubMedGoogle Scholar
  • 11 Kolte D, Khera S, Aronow WS. et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc 2014; 3 (03) e001056
    CrossrefPubMedGoogle Scholar
  • 12 Lee S, Cho GJ, Park GU. et al. Incidence, Risk Factors, and Clinical Characteristics of Peripartum Cardiomyopathy in South Korea. Circ Heart Fail 2018; 11 (04) e004134
    CrossrefPubMedGoogle Scholar
  • 13 Pfeffer TJ, List M, Schippert C. et al. High prevalence of reduced fertility and use of assisted reproductive technology in a German cohort of patients with peripartum cardiomyopathy. Clin Res Cardiol 2022; DOI: 10.1007/s00392-022-02034-x.
    CrossrefPubMedGoogle Scholar
  • 14 Pfeffer TJ, Schlothauer S, Pietzsch S. et al. Increased Cancer Prevalence in Peripartum Cardiomyopathy. JACC CardioOncol 2019; 1 (02) 196-205
    CrossrefPubMedGoogle Scholar
  • 15 Haghikia A, Podewski E, Libhaber E. et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol 2013; 108 (04) 366
    CrossrefPubMedGoogle Scholar
  • 16 Hilfiker-Kleiner D, Haghikia A, Berliner D. et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 2017; 38 (35) 2671-2679
    CrossrefPubMedGoogle Scholar
  • 17 Sliwa K, Blauwet L, Tibazarwa K. et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010; 121 (13) 1465-1473
    CrossrefPubMedGoogle Scholar
  • 18 Sliwa K, Petrie MC, van der Meer P. et al. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J 2020; 41 (39) 3787-3797
    CrossrefPubMedGoogle Scholar
  • 19 Blauwet LA, Delgado-Montero A, Ryo K. et al. Right Ventricular Function in Peripartum Cardiomyopathy at Presentation Is Associated With Subsequent Left Ventricular Recovery and Clinical Outcomes. Circ Heart Fail 2016; 9 (05) e002756
    CrossrefPubMedGoogle Scholar
  • 20 McDonagh TA, Metra M, Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42 (36) 3599-3726
    Google Scholar
  • 21 Moulig V, Pfeffer TJ, Ricke-Hoch M. et al. Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities. Eur J Heart Fail 2019; (12) 1534-1542
    CrossrefPubMedGoogle Scholar
  • 22 Stapel B, Kohlhaas M, Ricke-Hoch M. et al. Low STAT3 expression sensitizes to toxic effects of beta-adrenergic receptor stimulation in peripartum cardiomyopathy. Eur Heart J 2017; 38 (05) 349-361
    PubMedGoogle Scholar
  • 23 Elkayam U, Schäfer A, Chieffo A. et al. Use of Impella heart pump for management of women with peripartum cardiogenic shock. Clin Cardiol 2019; 42 (10) 974-981
    CrossrefPubMedGoogle Scholar
  • 24 Sieweke JT, Pfeffer TJ, Berliner D. et al. Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy. Eur Heart J Acute Cardiovasc Care 2020; 9 (02) 173-182
    CrossrefPubMedGoogle Scholar
  • 25 Al-Khatib SM, Stevenson WG, Ackerman MJ. et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2018; 15 (10) e190-e252
    CrossrefPubMedGoogle Scholar
  • 26 Duncker D, Haghikia A, König T. et al. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail 2014; 16 (12) 1331-1336
    CrossrefPubMedGoogle Scholar
  • 27 Duncker D, Westenfeld R, Konrad T. et al. Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. Clin Res Cardiol 2017; 106 (08) 582-589
    CrossrefPubMedGoogle Scholar
  • 28 Hilfiker-Kleiner D, Haghikia A, Masuko D. et al. Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. Eur J Heart Fail 2017; 19 (12) 1723-1728
    CrossrefPubMedGoogle Scholar